China Medical System Holdings Limited (HKG:0867)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 21.17B |
| Revenue (ttm) | 7.95B |
| Net Income (ttm) | 1.72B |
| Shares Out | 2.42B |
| EPS (ttm) | 0.71 |
| PE Ratio | 12.34 |
| Forward PE | 12.03 |
| Dividend | 0.29 (3.38%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 17,596,828 |
| Average Volume | 9,801,622 |
| Open | 8.85 |
| Previous Close | 8.76 |
| Day's Range | 8.63 - 9.14 |
| 52-Week Range | 6.23 - 10.28 |
| Beta | 0.91 |
| RSI | 61.76 |
| Earnings Date | May 15, 2025 |
About HKG:0867
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ... [Read more]
Financial Performance
In 2024, HKG:0867's revenue was 7.47 billion, a decrease of -6.79% compared to the previous year's 8.01 billion. Earnings were 1.62 billion, a decrease of -32.54%.
Financial numbers in CNY Financial StatementsNews
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
On Wednesday, Alpha Cognition Inc. (NASDAQ: ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Zun...